BioCentury
ARTICLE | Company News

QLT, sanofi-aventis, Takeda, Tap Holdings, Wako Pure Chemical cancer news

February 12, 2007 8:00 AM UTC

QLT said it and partner SAN will pay $112.5 million and $45 million, respectively, to settle a patent infringement lawsuit related to prostate cancer drug Eligard leuprolide acetate. In 2003, Takeda, Tap and Wako filed suit against Atrix (now part of QLT) and SAN in the U.S. District Court for the Northern District of Illinois alleging that Eligard infringed a patent held by Takeda and Wako. Under terms of the settlement, the parties granted QLT a non-exclusive, royalty-free license to market Eligard in the U.S. and Canada.

QLT said the settlement resolves only the U.S. litigation and does not affect ongoing litigation in Germany. The Takeda patent in that case has been declared invalid by a German court. Takeda has appealed the decision. ...